Comprehensive genomic and digital pathology profiling of tobacco-chewer female oral cancer patients simultaneously with integration of single-cell datasets identifies clinically actionable patient subgroups

Arnab Ghosh; Siddharth Singh; Tuneer R. Mallick; Shouvik Chakravarty; Supriya Varsha Bhagat; Chitrarpita Das; Kodaganur S. Gopinath; Azeem Mohiyuddin; Arindam Maitra; Partha P. Majumder; Tapas K. Kundu; Nidhan K. Biswas

doi:10.1002/ctm2.70386

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (7) : e70386 DOI: 10.1002/ctm2.70386

LETTER TO THE JOURNAL

Comprehensive genomic and digital pathology profiling of tobacco-chewer female oral cancer patients simultaneously with integration of single-cell datasets identifies clinically actionable patient subgroups

Author information +

History +

PDF

Cite this article

Download citation ▾

Arnab Ghosh, Siddharth Singh, Tuneer R. Mallick, Shouvik Chakravarty, Supriya Varsha Bhagat, Chitrarpita Das, Kodaganur S. Gopinath, Azeem Mohiyuddin, Arindam Maitra, Partha P. Majumder, Tapas K. Kundu, Nidhan K. Biswas. Comprehensive genomic and digital pathology profiling of tobacco-chewer female oral cancer patients simultaneously with integration of single-cell datasets identifies clinically actionable patient subgroups. Clinical and Translational Medicine, 2025, 15(7): e70386 DOI:10.1002/ctm2.70386

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	India Project Team of the International Cancer Genome Consortium. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun.2013; 4(11): 2873.

[2]	Pradhan S, Das S, Singh AK, et al. dbGENVOC: database of GENomic variants of oral cancer, with special reference to India. Database 2021; 2021: baab034.

[3]	Mathur P, Sathishkumar K, Chaturvedi M, et al Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. JCO Glob Oncol.2020; 6: 1063-1075.

[4]	Zhang H, Chen L, Li L, et al Prediction and analysis of tumor infiltrating lymphocytes across 28 cancers by TILScout using deep learning. NPJ Precis Oncol.2025; 9: 76.

[5]	Xiao G, Li L, Tanzhu G, et al Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. J Immunother Cancer.2023; 11: e006243.

[6]	Maron SB, Alpert L, Kwak HA, et al Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma. Cancer Discov.2018; 8: 696-713.

[7]	Thudium K, Selby M, Zorn JA, et al Preclinical characterization of relatlimab, a human LAG-3-blocking antibody, alone or in combination with nivolumab. Cancer Immunol Res.2022; 10: 1175-1189.

[8]	Heinemann V, Ebert MP, Laubender RP, et al Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer 2013; 108: 766-770.

[9]	H PC, W OP, Eva H, et al A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med.2025; 354: 899-910.

[10]	Li Q, Tie Y, Alu A, et al Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct Target Ther.2023; 8: 31.

[11]	Hanna GJ, Perez CA, Ho AL, et al A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with PIK3CA-mutated/amplified and/or HRAS-overexpressing recurrent/metastatic head and neck squamous cell carcinoma. J Clin Oncol.2025; 40: TPS6104-TPS6104.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.